Japan approves rheumatoid drug Baricitinib for COVID-19 patients

  • English
  • 日本語
  • 简体字
  • 繁體字
  • Français
  • Español
  • العربية
  • Русский

TOKYO (Reuters) - Japan's health ministry approved on Friday the use of rheumatoid arthritis drug Baricitinib for COVID-19 patients, the third such approval following the drugs remdesivir and dexamethasone.

Eli Lilly & Co's Japan subsidiary had applied to regulators for the new use of the drug in December.

(Reporting by Rocky Swift; Editing by Clarence Fernandez)

(c) Copyright Thomson Reuters 2021. Click For Restrictions -
https://agency.reuters.com/en/copyright.html

Reuters Japan Health United States Asia East Asia US